This Article Full Text (OnlineFirst PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Ozer, O. Articles by Akcay, M. PubMed PubMed Citation Articles by Ozer, O. Articles by Akcay, M. Social Bookmarking                         What's this?

Fibrinolytic Therapy of Prosthetic Mitral Valve Thrombosis During Pregnancy: Three Case Reports and Review of the Literature

^* To whom correspondence should be addressed. E-mail: oozer{at}gantep.edu.tr.

	Abstract

The incidence of prosthetic valve thrombosis (PVT), which is a life-threatening complication, increased during pregnancy because of the hypercoagulable state. Despite adequate anticoagulation, the incidence of PVT has been estimated as 4% to 14% during pregnancy. Prosthetic valve thrombosis occurring during pregnancy requires urgent therapy including fibrinolytic therapy, valve replacement, and surgical thrombectomy due to high mortality. Although surgery has traditionally been the standard procedure for treatment of PVT, fibrinolytic therapy may be used as first-line therapy according to data from the recent reports. Data about the fibrinolytic therapy is scarce and controversial in the setting of pregnancies complicated with PVT. Herein, we share the outcomes of 3 pregnant women complicated with PVT and treated with recombinant tissue-type plasminogen activator.

First published on October 13, 2009
Clinical and Applied Thrombosis/Hemostasis 2009, doi:10.1177/1076029609335517


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?